课题基金 / 基金详情

项目摘要

项目成果

Karen H Ashe的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary Our long-term goal is to understand the biological mechanisms underlying GWAS hits in LOAD and other tauopathies. The objective of our current proposal is to develop mouse models in which the entire 190 Kb human MAPT gene precisely replaces the complete 157 Kb mouse Mapt gene, and to use these models to compare the molecular endophenotypes of tau in young and old mice expressing H2 or H1 MAPT haplotypes. Our rationale is that the non-coding variants that define the H1 and H2 haplotypes are present in MAPT but not Mapt, necessitating the incorporation of the full MAPT gene. In addition, because we have found that the location of MAPT in the mouse genome affects its expression, we will preserve the basic structural configuration of Chr17q21.31 in which MAPT resides, and maintain its relationship relative to other genes in the gene cluster that mice and humans share. These studies will be significant because they will constitute the first in vivo bioassays of non-coding polymorphisms, paving the way for future research on GWAS hits in not only LOAD, but also other chronic medical disorders. Our overarching hypothesis is that differences in the progression and pattern of tau mRNA and protein expression underlie the variations in risk associated with H2 and H1 MAPT haplotypes. We have in-hand the first MAPT Gene-Replacement (GR) mouse line, in which the 190kb human H2 MAPT precisely replaces the 157 Kb Mapt locus, and will use the same methodology to create a precisely matched line in which the H1 MAPT replaces Mapt. We will measure and compare mRNA, protein and post-translational modifications of tau in young and old GR1 and GR2 mice. Upon completion of these studies, we will have created and characterized two lines of mice in which Mapt is precisely replaced by H1 or H2 variants of MAPT. We predict that the distinct polymorphisms in H1 and H2 MAPT will suffice to alter the molecular endophenotype of tau in GR1 relative to GR2 mice, and that these differences will increase with age.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Prodrugs of potent and selective protease inhibitors as tauopathy therapeutics
  • 批准号:
    10761291
  • 项目类别:
  • 资助金额:
    $35.0万
  • 财政年份:
    2023
  • 负责人:
    Karen H Ashe
  • 依托单位:
Caspase-2 Probe Compounds
  • 批准号:
    10532777
  • 项目类别:
  • 资助金额:
    $70.96万
  • 财政年份:
    2019
  • 负责人:
    Karen H Ashe
  • 依托单位:
Caspase-2 Probe Compounds
  • 批准号:
    10322438
  • 项目类别:
  • 资助金额:
    $71.04万
  • 财政年份:
    2019
  • 负责人:
    Karen H Ashe
  • 依托单位:
Caspase-2 Probe Compounds
  • 批准号:
    9974861
  • 项目类别:
  • 资助金额:
    $36.97万
  • 财政年份:
    2019
  • 负责人:
    Karen H Ashe
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: